This is a prospective, non-randomized, observational registry study evaluating theclinical outcomes of patients with autoimmune or post-infectious neuroinflammatorysyndromes receiving stem cell-derived biologics (including mesenchymal stem cells andexosomes) at Biocells Medical clinics. The study aims to track improvements inneurological function, inflammatory biomarkers, and patient-reported quality of lifefollowing individualized regenerative interventions.
Not Provided
Biological: Allogeneic MSC infusions (IV)
Optional T-reg therapy (experimental/compassionate-use basis)
Other Name: MSC-derived exosomes (IV or intranasal),Supportive immunomodulatory agents
Inclusion Criteria:
- • Age 6-70
- Diagnosis of one of the eligible syndromes by neurologist or immunologist
- Unresponsive or partially responsive to conventional therapy
- Informed consent provided
Exclusion Criteria:
- • Active malignancy
- Severe systemic infection
- Contraindications to IV biologics
Biocells Medical
Warsaw 756135, Poland
Not Provided